由Adis國際有限公司(現(xiàn)在是Wolters Kluwer Health的一部分)出版。ISSN: 1173 - 2563。臨床藥物調(diào)查為您提供了快速訪問最佳設(shè)計(jì)，同行審查的臨床和藥物經(jīng)濟(jì)學(xué)研究世界各地，讓您跟上最新的原始研究在這個(gè)令人興奮的領(lǐng)域。該雜志的目標(biāo)是快速出版涵蓋臨床藥物開發(fā)和治療使用的所有階段的原始研究。這包括臨床試驗(yàn)結(jié)果的研究,臨床pharmacoeconomic研究,藥物流行學(xué)研究有很強(qiáng)的鏈接優(yōu)化處方實(shí)踐一種藥物或一組藥物,臨床藥效學(xué)和臨床藥代動力學(xué)研究有很強(qiáng)的聯(lián)系臨床實(shí)踐,在某些情況下,藥效學(xué)和藥代動力學(xué)研究在健康的志愿者,但一些建立或聲稱對臨床處方進(jìn)行了討論。此外，還鼓勵符合這些標(biāo)準(zhǔn)的簡短通信和案例研究報(bào)告，以及給編輯的信。

Published by Adis International Limited (now part of Wolters Kluwer Health). ISSN: 1173-2563.Clinical Drug Investigation gives you rapid access to the best designed, peer reviewed clinical and pharmacoeconomic studies worldwide, allowing you to keep up to date with the latest original research in this exciting area. The Journal's aim is rapid publication of original research covering all phases of clinical drug development and therapeutic use of drugs. This includes clinical trials, outcomes research, clinical pharmacoeconomic studies, pharmacoepidemiology studies with a strong link to optimum prescribing practice for a drug or group of drugs, clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to clinical practice and, in some instances, pharmacodynamic or pharmacokinetic studies in healthy volunteers, but in which some established or purported implications for clinical prescribing are discussed. In addition, short communications and case study reports that meet these criteria are also encouraged, as are letters to the editor.